miR-21 Serves as Prognostic Biomarker in Triple-Negative Breast Cancer

miR-21 Serves as Prognostic Biomarker in Triple-Negative Breast Cancer
shutterstock_126772121Patients with triple-negative breast cancer (TNBC), or those individuals with breast cancer cells that do not express estrogen, progesterone, or human epidermal growth factor receptor 2 receptors (ER-/PR-/HER-), may be able to add miR-21 to the list of potential prognostic biomarkers. A study from The American Journal of Pathology, "Stromal Expression of miR-21 Identifies High-Risk Group in Triple-Negative Breast Cancer," identified altered miR-21 expression profiles in the tumor stroma of patients with TNBC. "Predictive biomarkers for therapeutic response prediction and novel therapeutic targets that address distinct biological features of TNBC subgroups are needed for these patients," said Lorenzo F. Sempere, PhD, head of the Laboratory of microRNA Diagnostics and Therapeutics at Van Andrel Research Institute, in a press release from the publishers. "These findings add support to the growing importance of miRNA-based diagnostics." Dr. Sempere's research team previously showed miR-21, a noncoding regulatory RNA that modul
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.